In 2021, based on the results from the CodeBreaK 100 trial (NCT03600883), the Food and Drug Administration (FDA) approved sotorasib (AMG-510) for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients previously treated with at least one systemic therapy [59]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.